Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price

LXRXStock

$2.29+99.13%52W

Market Cap$1.02B

P/E—

PEG Ratio-13.77

Div yield—

Beta1.05

LXRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)42.80%

Price vs S&P 500 (4W)-3.26%

PEG Ratio-13.77

VGM Score61.26

Book Value / Share (Quarterly)$0.48

P/TBV (Annual)3.09x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)692.66%

Cash Flow / Share (Quarterly)$-0.09

Price vs S&P 500 (YTD)86.31%

Gross Margin (TTM)99.49%

Net Profit Margin (TTM)-37.46%

EPS (TTM)$-0.07

10-Day Avg Trading Volume2.51M

EPS Excl Extra (TTM)$-0.07

Revenue Growth (5Y)15.72%

EPS (Annual)$-0.14

ROI (Annual)-31.16%

Gross Margin (Annual)99.45%

Net Profit Margin (5Y Avg)-29324.68%

Cash / Share (Quarterly)$0.40

Revenue Growth QoQ (YoY)1572.11%

ROA (Last FY)-27.21%

Revenue Growth TTM (YoY)123.12%

EBITD / Share (TTM)$-0.06

ROE (5Y Avg)-107.73%

Operating Margin (TTM)-34.79%

Cash Flow / Share (Annual)$-0.19

P/B Ratio5.15x

P/B Ratio (Quarterly)3.26x

Net Income / Employee (Annual)$-621,500

EV / Revenue (TTM)15.18x

Net Interest Coverage (TTM)-5.04x

ROA (TTM)-11.79%

EV / EBITDA (TTM)24.82x

EPS Incl Extra (Annual)$-0.14

Current Ratio (Annual)4.88x

Quick Ratio (Quarterly)18.43x

3-Month Avg Trading Volume3.13M

52-Week Price Return99.13%

Revenue / Employee (TTM)$859,800

Tangible BV / Share (Quarterly)$1.11

P/S Ratio (Annual)21.00x

Asset Turnover (Annual)0.27x

52-Week High$2.68

Operating Margin (5Y Avg)-28966.14%

EPS Excl Extra (Annual)$-0.14

CapEx CAGR (5Y)59.46%

Tangible BV CAGR (5Y)-7.47%

26-Week Price Return54.73%

Quick Ratio (Annual)4.73x

13-Week Price Return3.62%

Total Debt / Equity (Annual)0.50x

Current Ratio (Quarterly)18.79x

Enterprise Value$1.06B

Revenue / Share Growth (5Y)-8.73%

Asset Turnover (TTM)0.31x

Book Value / Share Growth (5Y)-23.17%

Revenue / Employee (Annual)$614,900

Inventory Turnover (Annual)1.07x

Pretax Margin (Annual)-101.08%

Cash / Share (Annual)$0.26

3-Month Return Std Dev58.58%

Gross Margin (5Y Avg)98.08%

Net Income / Employee (TTM)$-322,100

ROE (Last FY)-46.81%

Net Interest Coverage (Annual)-2.22x

EPS Basic Excl Extra (Annual)$-0.14

P/FCF (TTM)61.53x

Receivables Turnover (TTM)2.35x

Total Debt / Equity (Quarterly)0.24x

EPS Incl Extra (TTM)$-0.07

Receivables Turnover (Annual)17.01x

ROI (TTM)-13.44%

P/S Ratio (TTM)15.01x

Pretax Margin (5Y Avg)-29324.68%

Revenue / Share (Annual)$0.14

Tangible BV / Share (Annual)$1.11

Price vs S&P 500 (52W)80.57%

Year-to-Date Return99.13%

5-Day Price Return-1.29%

EPS Normalized (Annual)$-0.14

ROA (5Y Avg)-57.63%

Net Profit Margin (Annual)-101.08%

Month-to-Date Return-0.87%

Cash Flow / Share (TTM)$-0.76

EBITD / Share (Annual)$-0.13

Operating Margin (Annual)-98.21%

LT Debt / Equity (Annual)0.46x

ROI (5Y Avg)-68.66%

LT Debt / Equity (Quarterly)0.24x

EPS Basic Excl Extra (TTM)$-0.07

P/TBV (Quarterly)3.09x

P/B Ratio (Annual)3.89x

Inventory Turnover (TTM)1.48x

Pretax Margin (TTM)-37.46%

Book Value / Share (Annual)$0.30

Price vs S&P 500 (13W)1.67%

Beta1.05x

P/FCF (Annual)9.20x

Revenue / Share (TTM)$0.17

ROE (TTM)-18.64%

52-Week Low$1.03

vGradeD

gGradeA

mGradeB

vgmGradeB

LXRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.05	-$0.06	-24.83%(-$0.01)
Q1 2026	May 7, 2026	-$0.04	$0.00	+100.00%(+$0.04)
Q4 2025	Mar 5, 2026	-$0.07	-$0.04	+43.65%(+$0.03)
Q3 2025	Nov 6, 2025	-$0.07	-$0.04	+39.44%(+$0.03)
Q2 2025	Aug 6, 2025	-$0.08	$0.01	+112.90%(+$0.09)

LXRX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
LXRXLexicon Pharmaceuticals, Inc.	D	A	B	$2.29
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics. Its pipeline includes LX9211 and LX9851, oral drug candidates, with LX9851 targeting obesity and associated cardiometabolic disorders. The company focuses on commercializing treatments for significant unmet medical needs.